Sam Brusco, Associate Editor06.03.22
Minimally invasive peripheral vascular device firm Cardio Flow has received U.S. Food and Drug Administration (FDA) clearance for its FreedomFlow peripheral guidewire.
A stainless steel core-to-tip design and fixed distal-spring coil helps support diagnostic and therapeutic devices used to treat plaque blockages in arteries above and below the knee. The guidewire’s silicone-coated spring coil and silicone coating on the distal 200cm eases crossing of tough blockages. A 0.014-inch core-to-tip design also allows better transmission of torque and precise control.
The first commercial case using FreedomFlow was completed this past week by Dr. Jihad Mustapha, MD, FACC, FSCAI, the Director of Endovascular Interventions at Advanced Cardiac & Vascular Centers for Amputation Prevention.
“I was able to deliver three PTA balloons, one IVUS catheter, and a therapeutic device across the single guidewire—all glided easily along the FreedomFlow wire,” Dr. Mustapha told the press. “This new product has the potential to save time and costs in the endovascular lab, given its versatility in crossing occlusions and ability to deliver multiple interventional devices on a single guidewire.”
“Cardio Flow is encouraged by the initial feedback from Dr. Mustapha, who is a recognized leader in the treatment of PAD and critical limb ischemia (CLI),” added Cardio Flow VP of sales and marketing Scott Kraus. “We look forward to bringing this advancement in guidewire technology to our U.S. customers with a limited market release, followed by expanded commercial efforts in 2022.”
A stainless steel core-to-tip design and fixed distal-spring coil helps support diagnostic and therapeutic devices used to treat plaque blockages in arteries above and below the knee. The guidewire’s silicone-coated spring coil and silicone coating on the distal 200cm eases crossing of tough blockages. A 0.014-inch core-to-tip design also allows better transmission of torque and precise control.
The first commercial case using FreedomFlow was completed this past week by Dr. Jihad Mustapha, MD, FACC, FSCAI, the Director of Endovascular Interventions at Advanced Cardiac & Vascular Centers for Amputation Prevention.
“I was able to deliver three PTA balloons, one IVUS catheter, and a therapeutic device across the single guidewire—all glided easily along the FreedomFlow wire,” Dr. Mustapha told the press. “This new product has the potential to save time and costs in the endovascular lab, given its versatility in crossing occlusions and ability to deliver multiple interventional devices on a single guidewire.”
“Cardio Flow is encouraged by the initial feedback from Dr. Mustapha, who is a recognized leader in the treatment of PAD and critical limb ischemia (CLI),” added Cardio Flow VP of sales and marketing Scott Kraus. “We look forward to bringing this advancement in guidewire technology to our U.S. customers with a limited market release, followed by expanded commercial efforts in 2022.”